MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea

March 20, 2024 |

4 min read

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.

Site to supply products to customers for development and production of biologics
New Bioprocessing Production Center in Daejeon strengthens company’s footprint in fast-growing Asia-Pacific region
Investment to create up to 300 additional jobs

BURLINGTON, Mass.--(BUSINESS WIRE)-- MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea. The new site is the largest investment by the company’s Life Science business sector in Asia-Pacific to date and demonstrates its commitment to expanding its capacities in the fast-growing region. The investment is expected to create approximately 300 additional jobs by the end of 2028.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320070934/en/

Rendering of MilliporeSigma’s new Bioprocessing Production Center in Daejeon, South Korea (Photo: Business Wire)

“The Asia-Pacific region is home to a large number of institutions that conduct leading-edge and innovative research, manufacturing and services in areas such as biotechnology, mRNA and gene therapy,” said Matthias Heinzel, Member of the Executive Board and CEO Life Science, Merck KGaA, Darmstadt, Germany. “Expanding our presence in the region will bring us even closer to our customers in this evolving and dynamic market. Our goal is to foster deep collaboration to increase the speed in bringing new therapies to patients.”

The facility will support biotechnology and pharmaceutical companies in process development, clinical research and commercial manufacturing of biologics. Biologics are derived from large and complex biological compounds and include products like vaccines, cell and gene therapies, or protein-based therapies, such as monoclonal antibodies. They are one of the fastest-growing class of drugs.

MilliporeSigma’s new Bioprocessing Production Center will provide essential biotech products such as dry powder cell culture media, process liquids, pre-GMP small-scale manufacturing and sterile sampling systems. Covering an area of 43,000 square meters, the facility will include advanced production capacities, a distribution center and an automated warehouse.

Established in 1989, the Life Science business of Merck KGaA, Darmstadt, Germany in Korea has been consistently driving dynamic growth of the science and technology industries with more than 1,700 employees across Life Science, Healthcare and Electronics. It encompasses 13 sites in production and R&D including the M Lab™ Collaboration Center in Songdo, Incheon which serves biopharmaceutical companies in the region.

The company’s new site in South Korea is part of a multi-year investment program. This program aims to increase the capacity and capabilities of its Life Science business sector to support the growing global demand for critical drugs and to make significant contributions to public health. Since 2020, the company has announced industrial capacity and capabilities expansion projects in Life Science throughout Europe, China, and the United States, of more than € 2 billion.

About the Life Science business of Merck KGaA, Darmstadt, Germany

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.

Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.